A share price of Apellis Pharmaceuticals Inc [APLS] is currently trading at $27.58, up 2.22%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The APLS shares have lost -1.22% over the last week, with a monthly amount drifted -9.84%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
On May 31, 2024, Piper Sandler initiated with a Neutral rating and assigned a price target of $46 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $80 on February 05, 2024. Wells Fargo downgraded its rating to a Equal Weight. Goldman started tracking with a Buy rating for this stock on November 09, 2023, and assigned it a price target of $74. In a note dated November 02, 2023, Mizuho initiated an Neutral rating and provided a target price of $42 on this stock.
Apellis Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $26.28 and $73.80. Currently, Wall Street analysts expect the stock to reach $76.13 within the next 12 months. Apellis Pharmaceuticals Inc [NASDAQ: APLS] shares were valued at $27.58 at the most recent close of the market. An investor can expect a potential return of 176.03% based on the average APLS price forecast.
Analyzing the APLS fundamentals
Trailing Twelve Months sales for Apellis Pharmaceuticals Inc [NASDAQ:APLS] were 628.79M which represents 110.26% growth. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.53%, Pretax Profit Margin comes in at -0.54%, and Net Profit Margin reading is -0.54%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -1.39 and Total Capital is -0.44. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.75.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 26.85 points at the first support level, and at 26.11 for the second support level. However, for the 1st resistance point, the stock is sitting at 28.27, and for the 2nd resistance point, it is at 28.95.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Apellis Pharmaceuticals Inc [NASDAQ:APLS] is 5.08. In addition, the Quick Ratio stands at 4.18 and the Cash Ratio stands at 2.14. Considering the valuation of this stock, the price to sales ratio is 5.34, the price to book ratio is 12.70.
Transactions by insiders
Recent insider trading involved Dunlop A. Sinclair, Director, that happened on Sep 16 ’24 when 37000.0 shares were sold. VP/Chief Accounting Officer, Chopas James George completed a deal on Sep 16 ’24 to sell 192.0 shares. Meanwhile, Officer Chopas James George bought 192.0 shares on Sep 16 ’24.
